JP2024531259A5 - - Google Patents
Info
- Publication number
- JP2024531259A5 JP2024531259A5 JP2024508793A JP2024508793A JP2024531259A5 JP 2024531259 A5 JP2024531259 A5 JP 2024531259A5 JP 2024508793 A JP2024508793 A JP 2024508793A JP 2024508793 A JP2024508793 A JP 2024508793A JP 2024531259 A5 JP2024531259 A5 JP 2024531259A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- formula
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025284521A JP2026042844A (ja) | 2021-08-13 | 2025-12-26 | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233039P | 2021-08-13 | 2021-08-13 | |
| US63/233,039 | 2021-08-13 | ||
| PCT/US2022/074908 WO2023019244A1 (en) | 2021-08-13 | 2022-08-12 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025284521A Division JP2026042844A (ja) | 2021-08-13 | 2025-12-26 | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531259A JP2024531259A (ja) | 2024-08-29 |
| JP2024531259A5 true JP2024531259A5 (cg-RX-API-DMAC10.html) | 2025-08-20 |
| JP7804370B2 JP7804370B2 (ja) | 2026-01-22 |
Family
ID=83151645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508793A Active JP7804370B2 (ja) | 2021-08-13 | 2022-08-12 | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
| JP2025284521A Pending JP2026042844A (ja) | 2021-08-13 | 2025-12-26 | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025284521A Pending JP2026042844A (ja) | 2021-08-13 | 2025-12-26 | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11648225B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4384505A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7804370B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102985637B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN117940407A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3228242A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023019244A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12697320B2 (en) | 2021-01-29 | 2026-08-04 | Tim Therapeutics, Inc. | Tartaric acid analogs and uses thereof |
| CN117940407A (zh) | 2021-08-13 | 2024-04-26 | Lapix生物治疗股份有限公司 | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 |
| US20260144239A1 (en) | 2022-10-25 | 2026-05-28 | Lapix Therapeutics, Inc. | Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models |
| WO2024118602A1 (en) | 2022-11-29 | 2024-06-06 | Lapix Therapeutics, Inc. | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| US6004955A (en) | 1996-08-15 | 1999-12-21 | Dupont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists |
| US20040072802A1 (en) * | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
| DE10359829A1 (de) | 2003-12-12 | 2005-07-21 | Salama, Zoser B., Dr.Rer.Nat. | Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV |
| JP6783652B2 (ja) | 2013-09-24 | 2020-11-11 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 抗原特異的免疫原性を低減するための組成物及び方法 |
| JP6699011B2 (ja) * | 2014-07-04 | 2020-05-27 | 国立大学法人 東京大学 | 脂肪酸サロゲートを含むリゾホスファチジルセリン誘導体 |
| ES2952038T3 (es) | 2016-04-05 | 2023-10-26 | Univ New York State Res Found | Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune |
| EP3481866B1 (en) | 2016-07-06 | 2024-07-24 | Bristol-Myers Squibb Company | Combination of tim-4 antagonist and pd-1 antagonist and methods of use |
| AU2018323462A1 (en) | 2017-08-28 | 2020-03-26 | Bristol-Myers Squibb Company | TIM-3 antagonists for the treatment and diagnosis of cancers |
| US20240173389A1 (en) | 2021-03-11 | 2024-05-30 | Lapix Therapeutics, Inc. | Compositions and Methods For Reducing Immune Intolerance |
| EP4384495A1 (en) | 2021-08-13 | 2024-06-19 | Lapix Therapeutics, Inc. | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
| CN117940407A (zh) | 2021-08-13 | 2024-04-26 | Lapix生物治疗股份有限公司 | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 |
-
2022
- 2022-08-12 CN CN202280055815.2A patent/CN117940407A/zh active Pending
- 2022-08-12 JP JP2024508793A patent/JP7804370B2/ja active Active
- 2022-08-12 US US17/886,926 patent/US11648225B2/en active Active
- 2022-08-12 KR KR1020247007626A patent/KR102985637B1/ko active Active
- 2022-08-12 EP EP22762246.1A patent/EP4384505A1/en active Pending
- 2022-08-12 WO PCT/US2022/074908 patent/WO2023019244A1/en not_active Ceased
- 2022-08-12 CA CA3228242A patent/CA3228242A1/en active Pending
-
2023
- 2023-02-13 US US18/168,128 patent/US12016836B2/en active Active
-
2024
- 2024-05-09 US US18/659,715 patent/US12390434B2/en active Active
-
2025
- 2025-07-18 US US19/273,261 patent/US20250345302A1/en active Pending
- 2025-12-26 JP JP2025284521A patent/JP2026042844A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508705A5 (cg-RX-API-DMAC10.html) | ||
| US10232058B2 (en) | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy | |
| US9216956B2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| JP2020511943A5 (cg-RX-API-DMAC10.html) | ||
| TW201202262A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| JP2016505019A5 (cg-RX-API-DMAC10.html) | ||
| JP2019504087A5 (cg-RX-API-DMAC10.html) | ||
| JP2018519834A5 (cg-RX-API-DMAC10.html) | ||
| JP2013542963A5 (cg-RX-API-DMAC10.html) | ||
| JP2024522183A5 (cg-RX-API-DMAC10.html) | ||
| CA3176191A1 (en) | Treatment of proliferative diseases of the cns | |
| CN117940407A (zh) | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 | |
| JP2024504366A5 (cg-RX-API-DMAC10.html) | ||
| US20220002730A1 (en) | Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof | |
| Rietsema | Unexpected recovery of moderate cognitive impairment on treatment with oral methylcobalamin | |
| US20260083671A1 (en) | Stabilized formulation comprising recombinant stabilized galectin 9 protein | |
| RU2024105920A (ru) | Композиции и способы снижения иммунной непереносимости и лечения аутоиммунных расстройств | |
| US20170304433A1 (en) | Vaccine compositions and methods of use to treat neonatal subjects | |
| US20230119606A1 (en) | Immune cell modulators | |
| JP2024546654A5 (cg-RX-API-DMAC10.html) | ||
| ES2983628T3 (es) | Compuestos | |
| JP2023545788A (ja) | ジヒドロオロト酸デヒドロゲナーゼ(dhodh)阻害剤による自己免疫疾患の治療 | |
| BRPI0610351A2 (pt) | uso de compostos de triazina e medicamentos compreendendo os mesmos | |
| RU2019145035A (ru) | Новые ингибиторы cdk8/19 | |
| JP2021528479A5 (cg-RX-API-DMAC10.html) |